Dr. Jang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8081 Innovation Park Dr
Fairfax, VA 22031Phone+1 571-472-4724Fax+1 571-472-0241
Education & Training
- University of MinnesotaFellowship, Hematology and Medical Oncology, 2007 - 2010
- Albert Einstein Healthcare NetworkResidency, Internal Medicine, 2004 - 2007
- Seoul National University College of MedicineClass of 2001
Certifications & Licensure
- VA State Medical License 2014 - 2026
- DC State Medical License 2010 - 2018
- MD State Medical License 2011 - 2018
- MN State Medical License 2009 - 2011
- PA State Medical License 2004 - 2007
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013
Clinical Trials
- A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2012 Jun 03
Publications & Presentations
PubMed
- Real-world treatment patterns and outcomes of patients with advanced melanoma treated with nivolumab plus relatlimab.Sach Thakker, Micah Belzberg, Sekwon Jang, Jafar Al-Mondhiry
The Oncologist. 2024-12-06 - 1 citationsMerkel cell carcinoma.Sach Thakker, Suraj Venna, Micah Belzberg, Sekwon Jang, Jennifer DeSimone
Journal of the American Academy of Dermatology. 2024-09-01 - Managing large cutaneous squamous cell carcinoma with programmed cell death protein 1 inhibitor monotherapy: Real-world experience at a single center.Sach Thakker, Mairead R Baker, Jafar Al-Mondhiry, Sekwon Jang, Jennifer A DeSimone
JAAD International. 2024-09-01
Press Mentions
- Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage MelanomaJune 16th, 2020
- Personalis, Inc. To Present New Data at the Society for Immunotherapy of Cancer’s (SITC) 33November 9th, 2011
Other Languages
- Korean
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: